09:00 am – 4:30 pm
DZNE, Sigmund‐Freud‐Str. 27, 53127 Bonn
Afraxis attendee, Ron Demuth, was invited to the inauguration of the German Center for Neurodegenerative Diseases (DZNE) in Bonn Germany on March 15-16. The Center’s new research cluster in Bonn, on the campus of the University Hospital of Bonn, is the central hub for DZNE’s activities spread across nine sites and more than thirty clinics through Germany. The inauguration was hosted by Professor Dr. Pierluigi Nicotera, Director of DZNE, and attended by German Chancellor Angela Merkel and Minister Svenja Schulze of North Rhine-Westphalia.

Following the inauguration on March 15, DZNE sponsored a day-long International Symposium “New perspectives for Neurodegenerative Diseases”, at which the leaders of most national and international brain health and disease programmes presented their most recent achievements and future plans.

Afraxis is DZNE’s partner in an integrated collaboration focused on bringing academic-stage translational treatments into commercial development of clinical therapies for neurodegeneration diseases.

The partners in this project, announced in 2016, include DZNE, Afraxis, Chemical Diversity, and Torrey Pines Investment, see here.
DZNE contributes its early-stage expertise in translational medicine to the collaboration, while ChemDiv and Afraxis bring commercial drug development expertise and project management, and Torrey Pines Investment brings seed stage funding and investor networks to bear on the problems of delivering new clinical therapies to combat neurodegeneration and improve the lives of patients suffering from the broad family of neurodegenerative diseases.